Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.


Creative Commons License

ANTONIA S., VILLEGAS A., DANIEL D., VICENTE D., MURAKAMI S., HUI R., ...Daha Fazla

The New England journal of medicine, cilt.379, ss.2342-2350, 2018 (SCI-Expanded, Scopus) identifier identifier identifier